<DOC>
	<DOC>NCT01189487</DOC>
	<brief_summary>Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.</brief_summary>
	<brief_title>The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<criteria>16 years of age or older. Patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization. Known or suspected hypersensitivity or intolerance to ampicillin sodium/sulbactam sodium, other penicillins, or cephems. Hepatic dysfunction [Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT), total bilirubin &gt; 3 times upper limit of normal range values]. Severe renal dysfunction (creatinine clearance &lt; 30 ml/min). Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ampicillin sodium/sulbactam sodium</keyword>
	<keyword>Unasyn-S</keyword>
	<keyword>community acquired pneumonia</keyword>
	<keyword>bacterial pneumonia</keyword>
</DOC>